Public and Regulatory Policy
Public and Regulatory Policy Committee
Chair: Erin Davis
Our mission is to advocate on behalf of ICCAC by influencing international, regional, and state public policies relating to mechanical circulatory support. As a committee, we monitor legislation and regulatory agencies as they relate to MCS. These include but are not limited to, NIH, FDA, CMS, the Joint Commission, DNV, UNOS, and other international or regional regulatory bodies. Our vision is to review upcoming regulatory changes, inform our members about open comment periods, and create relevant society-level responses, approved by the ICCAC Board of Directors, to be delivered to appropriate regulatory bodies.
Have 1st meeting End of Aug 2022 to review and confirm these bylaws and determine deliverables for the next 2 quarters
Review which regulatory bodies will be followed closely by this committee and confirm with Executive Board
CDC / Coding Clinic
NIH & other European Regulatory Bodies as applicable
Other International Regulatory Bodies
Chair and Committee Member Requirements
- At least 3 members are recommended to maintain the efficiency of the committee. There is no maximum number of members.
- Recommend at least 1 international member, but not a requirement. Any International ICCAC member is invited to join committee calls to bring to attention international policies or regulations relating to MCS therapy
- Recruitment is achieved through current ICCAC membership, MCS collaboration board, emails, social media, and word of mouth via colleagues
- Chair of the committee is strictly voluntary and the individual who volunteers shall remain in the chair position for a minimum of 1 year
- If there are no other volunteers to follow the Chair position, the individual in the chair position can maintain in this role until another volunteer is found
- Co-Chair (if established) will take over January of the following year and will change to “Chair” status at to which time active recruitment for future co-chairs will take place
- Minimum 1 year as MCS clinician
- Active ICCAC Member
- Active committee members must participate in >50% of meeting phone calls. Should schedule conflicts occur, an email including project updates will suffice.
- Industry ICCAC members may fully participate in the committee, but may not hold the Chair or Co-Chair position
Scope and Objectives
- Monitor legislation and regulations involving MCS therapies and report to ICCAC Board Quarterly. These include, but are not limited to, NIH, FDA, CMS, the Joint Commission, DNV, UNOS, and other international or regional regulatory bodies that the committee is made aware of by International ICCAC members.
- Inform ICCAC membership of upcoming policy and regulation changes relating to MCS therapy
- Create society-level responses to open public comment periods for MCS therapy–related policy or regulation changes
If you have any questions, please contact ICCAC@VADCoordinator.org.